SCHEMBL20239238

SCHEMBL20239238

CN(C(=O)O)S(=O)(=O)Cc1ccc(Oc2cc(C#N)nc(C(F)(F)F)n2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
CACNA1B Q00975 2/20 0.35
CACNA1H O95180 2/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LIPE Q05469 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
DAGLA Q9Y4D2 1/20 0.33
SCN9A Q15858 1/20 0.33
LOXL2 Q9Y4K0 4/20 0.33
LOX P28300 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
BMP1 P13497 1/20 0.32
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20252432 0.89 KDM4E (0.33) KDM4ELMNACACNA1BCACNA1HMAPT
SCHEMBL20239334 0.87 SMN1; SMN2 (0.40) KDM4ELMNAMAPTL3MBTL1LIPE
SCHEMBL16738672 0.87 PDE2A (0.36) KDM4ELMNAALDH1A1GLATRPM8
SCHEMBL20239283 0.85 SMN1; SMN2 (0.34) KDM4ELMNACACNA1BCACNA1HMAPT
SCHEMBL20239142 0.85 ALDH1A1 (0.36) MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL20239225 0.84 LOXL2 (0.37) KDM4ECACNA1BCACNA1HMAPTL3MBTL1
SCHEMBL20239134 0.83 PTPN1 (0.33) LMNASCN9AALDH1A1HTTSMN1; SMN2
SCHEMBL20239258 0.82 PDE4B (0.34) KDM4ELMNAMAPTSCN9APDE4B
SCHEMBL16738676 0.77 GPR119 (0.36) LMNASCN9AALDH1A1GLAHTT
SCHEMBL20252426 0.75 SMN1; SMN2 (0.38) KDM4ELMNAMAPTL3MBTL1LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT KDM4E 4070/4885LMNA 2022/4885CACNA1B 2950/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT KDM4E 3891/4885LMNA 1722/4885CACNA1B 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.